StreetAlpha.app
Home › Stocks › XLO

Xilio Therapeutics, Inc. (XLO)

$7.56
▲ +0.67%
LAST CLOSE · NOV 20

Xilio Therapeutics develops masked immunotherapy treatments that activate inside tumors to treat cancer. It last closed at $7.56 on Nov 20, up 0.67% on the day. The next earnings report for XLO is expected around Mon, Mar 22, 2027. For the quarter ended Sep 2026, XLO reported EPS of -$0.30 on revenue of $10.0M, with revenue down 47.6% from a year ago. Over its last 8 reports the stock moved an average of 3.5% the session after earnings. Over the last 12 months XLO insiders bought $44K of stock on the open market and sold $6K, according to SEC Form 4 filings.

AI Auto Pilots
Is XLO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold XLO.

Key Stats

Last 12 months
Results
Revenue
$55.0M
+73.0% vs a year ago
Net income
−$11.5M
−20.9% margin
Free cash flow
−$57.6M
−104.8% margin
Operating margin
−74.9%
−$41.2M operating income
Valuation
Market cap
$53.4M
7.1M shares
P/E
–
Price to sales
1.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$122.2M
At Sep 30
Shareholder equity
$68.2M
Shares outstanding
7.1M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $6.3M$6.3MFY2024FY2025: $43.8M$43.8MFY2025

From XLO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 22
Estimated date · Time not announced
Reported EPS
-$0.30
Quarter ended Sep 2026
Year ago EPS
-$1.58
Same quarter last year
Revenue
$10.0M
−47.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$14.33Dec '24Mar 2025: -$2.49Mar '25Jun 2025: -$2.30Jun '25Sep 2025: -$1.58Sep '25Dec 2025: $1.84Dec '25Mar 2026: -$0.58Mar '26Jun 2026: -$0.33Jun '26Sep 2026: -$0.30Sep '26Latest -$0.30
Revenue by quarter
Dec 2024: $1.7MDec '24Mar 2025: $2.9MMar '25Jun 2025: $8.1MJun '25Sep 2025: $19.1MSep '25Dec 2025: $13.7MDec '25Mar 2026: $12.6MMar '26Jun 2026: $18.7MJun '26Sep 2026: $10.0MSep '26Latest $10.0M
How XLO moved after its last 8 reports
Average move the session after a report ±3.5%
Nov 10, 2026Time not announced−5.2%
Aug 12, 2026Time not announced−1.4%
May 12, 2026Time not announced0.0%
Mar 23, 2026Time not announced0.0%
Jan 8, 2026Time not announced+2.6%
Nov 13, 2025Time not announced−9.3%
Aug 14, 2025Time not announced−1.7%
May 8, 2025Time not announced+8.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on XLOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on XLO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on XLO

Technical Analysis

XLO · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 7% below its 20 day and 13% below its 50 day average. It is 12% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the swing low (Jun 5) at $7.53, and the nearest resistance the Pivot R1 at $7.75.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.9%/day
Key levels
$11.2052 week high+48.1%
$8.81100 day average+16.5%
$8.5650 day average+13.2%
$8.48200 day average+12.2%
$8.33Swing high (Jun 8)+10.2%
$8.0920 day average+7.0%
$7.75Pivot R1+2.5%
$7.56Last close
$7.53Swing low (Jun 5)−0.4%
$7.41Pivot−2.0%
$7.22Pivot S1−4.5%
$6.4752 week low−14.4%
Indicators
RSI (14)37.86Weak, oversold below 30Neutral
MACD-0.25Below its signal lineBearish
Stochastic25.6Middle of its rangeNeutral
ADX (14)29.9Trending down
Williams %R-74.4Oversold below −80, overbought above −20Neutral
CCI (20)-108.5Oversold below −100, overbought above 100Oversold
Rate of change−12.3%Change over 10 sessionsBearish
ATR (14)$0.60Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XLO

What happened before

See how XLO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow XLO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How XLO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for XLOHow many large options trades hit XLO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

XLO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲16 buying vs 7 selling
  • ▲Held by funds +5.3 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3026+15.4%
In funds' top 10110.0%
Held by funds53.5%48.2%+5.3 pts
New / increased7 / 910 / 4+14.3%
Reduced / sold out4 / 34 / 7−36.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XLO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

XLO Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$44K1 buy · 1 insider
Sold$6K2 sales · 2 insiders
100% of the selling was under pre-arranged trading plans.
2026-01 sold $6K2026-03 bought $44KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Mar 26James Samuel ShannonDirectorBuy5,000$8.79$44K
Jan 2Christopher James FrankenfieldCFOSale plan7,030$0.64$4K
Jan 2Kevin M. BrennanSvp, Finance And AccountingSale plan1,826$0.64$1K
Jun 17, 2025James Samuel ShannonDirectorBuy70,000$0.69$48K
Jun 16, 2025Rene RussoPresident And CEOBuy36,289$0.68$25K
Jan 2, 2025Kevin M. BrennanSvp, Finance And AccountingSale plan1,803$0.98$2K
Every insider buy and sale for XLO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See XLO insider trades →

From SEC Form 4 filings by XLO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XLO is in one of them and how their past XLO trades turned out.

XLO in the AI portfolios
Loading…

XLO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XLO in an article yet. Here's the latest on the wider market.

XLO in the news

About Xilio Therapeutics

Xilio Therapeutics is a biotechnology company that discovers and develops cancer immunotherapies designed to stay inactive until they reach tumors. Enzymes found in tumors remove the mask, which aims to limit activity in healthy tissue. Its pipeline includes a masked IL-2 fusion protein and masked T cell engagers, and it has partnerships with AbbVie and Gilead. The company is based in Waltham, Massachusetts, and is developing its treatments for patients with cancer.

Headquarters
Waltham, MA